Pyrimidine derivatives have proved to be of great importance in exhibiting therapeutic applications\[[@CIT1]\]. A large number of pyrimidine nucleosides are clinically useful for the control of retroviral infections\[[@CIT2]--[@CIT5]\]. One of the important class of anti-herpetic nucleosides is series of 5-substituted uracil nucleosides such as (E)-5-(2-bromovinyl)-2\'-deoxyuridine (BVdu)\[[@CIT6]\] showed specific antivaricella zoster virus (VZV) activity. In view of effect of 5-substitution on the activity of thiouracil, synthesis and antithyroid activity of several 5-substituted pyrimidine derivatives have been reported\[[@CIT7]\]. In addition, 5-alkyl or 5-aryl-substituted pyrimidine derivatives are useful intermediates in the synthesis of nucleosides\[[@CIT8]\]. Also, many 5-substituted pyrimidines have shown inhibitory activity against *Streptococcus faecalis* R growth\[[@CIT9]\] and some are evaluated as inhibitors of enzymes involved in the pyrimidine catabolism like dihydrouracil dehydrogenase and uridine phosphorylase\[[@CIT10]\]. Further, 5-iodo substituted pyrimidine analogs are known for their antimicrobial\[[@CIT11]\] and antiviral activity\[[@CIT12][@CIT13]\]. Synthesis and biological activities of several compounds derived from pyrimidine analogs were reported from our laboratory\[[@CIT10][@CIT14][@CIT15]\]. We report herein the synthesis and antimicrobial activities of 4-amino-5-iodo-2-benzylthiopyrimidines (3a-g) and 4-aryl/heteroarylidenehydrazino-5-iodo-2-benzylthiopyrimidines (4a-h).

Melting points were recorded by using Thomas-Hoover melting point apparatus and were uncorrected. IR spectra in KBr disc were recorded on Perkin-Elmer-Spectrum-one FT IR spectrophotometer (v~max~ in cm^−1^) and ^1^H NMR in DMSO-*d~6~* and/or CDCl~3~on amx 400, 400 MHz spectrophotometer using TMS as internal standard (chemical shift in δ ppm). Mass spectra were recorded on a Jeol SX 102 Mass spectrometer using argon/xenon (6kv, 10 mA) as the FAB gas. Purity of the compounds was checked by TLC using silica gel 'G' plates obtained from Whatman Inc, and a fluorescent indicator. 5-Iodo-2-benzylthiouracil (1) was prepared by following the known literature method\[[@CIT7]\].

General procedure for the synthesis of 4-chloro-5-iodo-2-benzylthiopyrimidine (2) is as follows, to a mixture of 5-iodo-2-benzylthiouracil (1) (0.01 mol) and POCl~3~ (0.06 mol) was refluxed for 1 h. Excess POCl~3~ was distilled under reduced pressure and the reaction mixture was poured into 200 ml of ice cold water. The solid separated was extracted with ether (3 × 100 ml) and the ether extracts were washed with 5% aq. NaHCO~3~ solution (3 × 100 ml), followed by water (3 × 100 ml). Ether layer was dried over anhydrous MgSO~4~. Solvent was evaporated to produce pale yellow syrup. The syrup slowly solidified and recrystallized from ethanol; 2: IR (KBr, cm^−1^): 3026 (aromatic C-H str), 1599 (C=N). ^1^H NMR (CDCl~3~): δ 8.69 (1H, s, Ar-H, Pyrimidine), 7.44-7.26 (5H, m, Ar-H), 4.36 (2H, s, S-CH~2~ -Ph).

General procedure for the synthesis of 4-amino-5-iodo-2-benzylthiopyrimidines (3a-g) is as follows, to a solution of 4-chloro-5-iodo-2-benzylthiopyrimidine (0.001 mol) in methanol (20 ml) and pyridine (0.5 ml), appropriate primary amine (0.001 mol) was added. The reaction mixture was refluxed for 4 h on a steam-bath. Excess of methanol was removed under reduced pressure and the residue triturated with a little crushed ice and aqueous layer was neutralized with 0.1N HCl. Solid separated was filtered and washed with cold water. Recrystallized the crude product from ethanol furnished the desired compounds (3a-g); 3a: IR (KBr, cm^−1^): 3379 (N-H), 1598 (C=N). ^1^H NMR (DMSO-d~6~): δ 8.27 (1H, s, Ar-H, pyrimidine), 7.68 (1H, s, N-H), 7.33-7.07 (9H, m, Ar-H), 4.17 (2H, s, S-CH~2~ -Ph), 2.27 (3H, s, CH~3~). MS m/z: 433 (M^+^) and fragmented peaks at 341, 308, 214. Analysis calculated for C~18~H~16~IN~3~S: C, 50.0; H, 3.73; N, 9.72. Found: C, 49.98; H, 3.70; N, 9.65%; 3b: IR (KBr, cm^−1^): 3300 (N-H), 1580 (C=N). ^1^H NMR (CDCl~3~): δ 8.22 (1H, s, Ar-H, pyrimidine), 8.03 (1H, s, N-H), 7.7-6.78 (9H, m, Ar-H), 4.31 (2H, s, S-CH~2~-Ph), 3.7 (3H, s, OCH~3~). Analysis calculated for C~18~H~16~IN~3~ OS: C, 48.21; H, 3.571; N, 9.372. Found: C, 48.18; H, 3.565; N, 9.365%; 3c: IR (KBr, cm^−1^): 3447 (N-H), 1603 (C=N), 1525 (NO~2~). ^1^H NMR (CDCl~3~): δ 8.5 (1H, s, Ar-H, pyrimidine), 7.4-7.26 (10H, m, Ar-H, N-H), 4.38 (2H, s, S-CH~2~-Ph). Analysis calculated for C~17~H~13~IN~4~O~2~S: C, 43.83; H, 2.281; N, 12.09. Found: C, 43.78; H, 2.275; N, 12.05%; 3d: IR (KBr, cm^−1^): 3356 (N-H), 1602 (C=N), 1539 (NO~2~). ^1^H NMR (DMSO-d~6~): δ 8.69 (1H, s, Ar-H, pyrimidine), 8.4 (1H, s, N-H) 7.98-7.22 (9H, m, Ar-H), 4.39 (2H, s, S-CH~2~-Ph); 3e: IR (KBr, cm^−1^): 3402 (NH~2~), 3303 (NH), 1616 (C=N). ^1^H NMR (CDCl~3~): δ 8.34 (1H, s, Ar-H, pyrimidine), 7.23-6.8 (12H, m, Ar-H, N-H), 4.12 (2H, s, S-CH~2~-Ph). MS m/z: 434 (M^+^) and fragmented ion peaks at 342, 214. Analysis calculated for C~17~H~15~IN~4~S: C, 47.11; H, 3.464; N, 12.93. Found: C, 47.08; H, 3.460; N, 12.88%; 3f: IR (KBr, cm^−1^): 3427 (N-H), 1602 (C=N). ^1^H NMR (CDCl~3~)~:~ δ 8.5 (1H, s, Ar-H, pyrimidine), 7.40-7.26 (10H, m, Ar-H, N-H), 4.38 (2H, s, S-CH~2~-Ph). Analysis calculated for C~16~H~13~IN~4~S: C, 45.73; H, 3.126; N, 13.33. Found: C, 45.71; H, 3.120; N, 13.28%; 3g: IR (KBr, cm^−1^): 3303 (NH~2~), 3239 (N-H), 1624 (C=N). ^1^H NMR (DMSO-d~6~): δ 7.82 (1H, s, Ar-H, pyrimidine), 7.29 (1H, s, N-H), 7.26-6.9 (5H, m, Ar-H), 4.04 (2H, s, S-CH~2~-Ph), 3.83 (2H, s, NH~2~). MS m/z: 358 (M^+^) and fragmented ion peak at 342, 231. Analysis calculated for C~11~H~11~IN~4~S: C, 36.97; H, 3.083; N, 15.68. Found: C, 36.90; H, 3.080; N, 15.64%.

General procedure for the synthesis of 4-aryl/heteroarylidinehydrazino-5-iodo-2-benzylthiopyrimidines (4a-h) as follows, to a solution of 4-hydrazino-5-iodo-2-benzylthiopyrimidine (3 g, 0.001 mol) in ethanol (20 ml) and catalytic amount of concentrated HCl, appropriate aromatic aldehyde (0.001 mol) was added. The reaction mixture was refluxed for 4 h. Excess ethanol was removed under reduced pressure, solid separated was filtrated and recrystalised from ethanol to get the desired compounds; 4a: IR (KBr, cm^−1^): 3419 (N-H), 1628 (C=N). ^1^H NMR (DMSO-d~6~): δ 8.69 (1H, s, Ar-H, pyrimidine), 8.27 (1H, s, N-H), 7.62 (1H, s, N=CH), 7.37-6.84 (10H, m, Ar-H, O-H), 4.41 (2H, s, S-CH~2~-Ph). Mass: m/z 462 (M^+^) and fragmented ion peak at 385, 336. Analysis calculated for C~18~H~15~IN~4~OS: C, 46.76; H, 3.271; N, 12.13. Found: C, 46.70; H, 3.270; N, 12.08%; 4b: IR (KBr, cm^−1^): 3414 (N-H), 1608 (C=N). ^1^H NMR (DMSO-d~6~): δ 8.42 (1H, s, Ar-H, pyrimidine), 8.28 (1H, s, NH), 7.72 (1H, s, N=CH), 7.69-6.83 (9H, m, Ar-H), 4.39 (2H, s, S-CH~2~-Ph), 3.7 (3H, s, OCH~3~). MS m/z: 476 (M^+^) and fragmented ion peak at 455, 349. Analysis calculated for C~19~H~17~IN~4~OS: C, 48.01; H, 3.57; N, 11.78. Found: C, 47.98; H, 3.5; N, 11.77%; 4c: IR (KBr, cm^−1^): 3380 (N-H), 1616 (C=N). ^1^H NMR (DMSO-d~6~): δ 8.32 (1H, s, Ar-H, pyrimidine), 8.25 (1H, s, N-H), 7.54 (1H, s, N=CH), 7.5-6.8 (9H, m, Ar-H, OH), 4.42 (2H, s, S-CH~2~-Ph), 3.59 (3H, s, OCH~3~). Analysis calculated for C~19~H~17~IN~4~O~2~S: C, 46.43; H, 3.462; N, 11.38. Found: C, 46.39; H, 3.460; N, 11.37%; 4d: IR (KBr, cm^−1^): 3453 (N-H), 1604 (C=N). ^1^H NMR (DMSO-d~6~): δ 8.49 (1H, s, Ar-H, pyrimidine), 8.3 (1H, s, N-H), 7.68-7.14 (10H, m, Ar-H, N=CH), 4.41 (2H, s, S-CH~2~-Ph). MS: m/z 480 (M^+^) and fragmented ion peak at 369, 353; 4e: IR (KBr, cm^−1^): 3400 (N-H), 1618 (C=N); ^1^H NMR (DMSO-d~6~): δ 8.73 (1H, s, Ar-H, pyrimidine), 8.04 (1H, s, N-H), 7.26 (1H, s, N=CH), 7.19-6.87 (9H, m, Ar-H), 4.16 (2H, s, S-CH~2~-Ph). Analysis calculated for C~18~H~14~ClIN~4~S: C, 45.04; H, 2.919; N, 11.67. Found: C, 45.01; H, 2.915; N, 11.65%; 4f: IR (KBr, cm^−1^): 3440 (N-H), 1616 (C=N). ^1^H NMR (DMSO-d~6~): δ 8.76 (1H, s, Ar-H, pyrimidine), 8.66 (1H, s, N-H), 8.36 (1H, s, N=CH), 8.05-7.04 (8H, m, Ar-H), 4.41 (2H, s, S-CH~2~-Ph). Analysis calculated for C~16~H~13~IN~4~S~2~: C, 42.57; H, 2.882; N, 12.41. Found: C, 42.54; H, 2.886; N, 12.42%; 4g: IR (KBr, cm^−1^): 3356 NH~2,~ 1605 C=N. ^1^H NMR (DMSO-d~6~): δ 9.2 (1H, s, Ar-H, pyrimidine), 8.66 (1H, s, N-H), 8.39 (1H, s, N=CH), 8.39-6.82 (10H, m, Ar-H, NH~2~), 4.43 (2H, s, S-CH~2~-Ph). MS: m/z 462 (M^+^) and fragmented ion peak at 325, 275. Analysis calculated for C~17~H~15~IN~6~S: C, 44.27; H, 3.253; N, 18.22. Found: C, 44.24; H, 3.246; N, 18.20%; 4h: IR (KBr, cm^−1^): 3380 (N-H), 1616 (C=N); ^1^H NMR (DMSO-d~6~): δ 9.1 (s, 1H, Ar-H, pyrimidine), 9.01 (1H, s, N-H), 7.85-7.42 (17H, m, Ar-H, N=CH), 4.43 (2H, s, S-CH~2~-Ph). MS m/z: 588 (M^+^) and fragmented ion peak at 493, 295. Analysis calculated for C~27~H~21~IN~6~S~2~: C, 55.19; H, 3.577; N, 14.31. Found: C, 55.12; H, 3.569; N, 14.25%.

The antimicrobial activities were performed by cup plate method\[[@CIT14]\]. The sample was dissolved in DMF at the concentration of 1000 μg/ml. Compounds were screened for antibacterial activity against *P. aeruginosa, E. coli, B. subtilis* and *S. aureus*. Antifungal activity was carried out against *A. terrus* and *A. niger* under aseptic conditions. Gentamycine and fluconazole were used as standard drug for antibacterial and antifungal activities, respectively. The zone of inhibition was compared with standard drug after 24 h of incubation at 25° for antibacterial activity and 48 h at 30° for antifungal activity.

The starting material 4-chloro-5-iodo2-benzylthiopyrimidine (2) was prepared by chlorination of 5-iodo-2-benzylthiouracil with excess POCl~3~ ([Scheme 1](#F0001){ref-type="fig"}). Compound 2 obtained as yellow crystals having the melting point 90-91° in 80% yield. IR spectrum of compound 2 exhibited absorption at 3026 and 1599 cm^−1^ due to (aromatic C-H str), (C=N), respectively. ^1^H NMR signals are at δ 8.69 (1H, s, Ar-H, pyrimidine), 7.44-7.26 (5H, m, Ar-H), 4.36 (2H, s, S-CH~2~-Ph). Reaction of 2 with various substituted aromatic amines, 2-aminopyridine and hydrazine hydrate gave desired compounds 3a-g in 40-75% yield. Compound 3a obtained as yellow colored solid having melting point 80-82° in 55% yield. IR spectrum of compound 3a shows characteristic absorption of (N-H) at 3379, (C=N) at 1598 cm^−1^. ^1^H NMR signals at δ 8.27 (1H, s, Ar-H, pyrimidine), 7.68 (1H, s, N-H), 7.33-7.07 (9H, m, Ar-H), 4.17 (2H, s, S-CH~2~-Ph), 2.27 (3H, s, CH~3~). Further compound 3a was confirmed by mass spectra analysis, the molecular ion peak at 433 (M^+^) and fragmented ion peaks at 342, 214. Compound 3g obtained as colorless crystals having the melting point 120-121° in 65% yield. IR spectrum of compound 3g shows absorption of (NH~2~) at 3303, (N-H) at 3239 and (C=N) at 1624 cm^−1^. The ^1^H NMR of 3g shows signal at δ 7.82 (1H, s, Ar-H, pyrimidine), 7.29 (1H, s, NH), 7.26-6.9 (5H, m, Ar-H), 4.04 (2H, s, S-CH~2~-Ph), 3.83 (2H, s, NH~2~). Mass spectra of compound 3g shows molecular ion peak at 358 (M^+^) and fragmented ion peak at 342, 231. Reaction of compound 3g with substituted aromatic and heterocyclic aldehydes furnished desired compounds 4-(aryl/heteroarylidinehydrazino)-5-iodo-2-benzylthiopyrimidines (4a-h) in 60-75% yield. The compound 4a was obtained as yellow colored solid in 75% yield, having m.p. 210-212°. The IR spectrum of compound 4a shows characteristic absorption of (O-H) at 3419, (N-H) at 3166 and (C=N) at 1621 cm^−1^. The ^1^H-NMR signals are at δ 8.6 (1H, s, Ar-H, pyrimidine), 8.2 (1H, s, NH), 7.6 (1H, s, N=CH), 7.3-6.8 (10H, m, Ar-H, OH).,4.4 (2H, s, S-CH2-Ph). Further compound 4a was confirmed by mass spectral analysis, the molecular ion peak at 462 (M^+^) and fragmented ion peak at 385, 336. Compound 4h was obtained as green colored solid in 52% yield, having m.p.210-211°. IR spectrum of compound 4h shows characteristic absorption of (N-H) at 3380, (C=N) at 1616 cm^−1^. ^1^H NMR signals are at δ 9.1 (1H, s, Ar-H, pyrimidine), 9.01 (1H, s, NH), 7.85-7.42 (17H, m, Ar-H, N = CH), 4.43 (2H, s, S-CH~2~-Ph). Further compound 4h was confirmed by mass spectra analysis, the molecular ion peak at 588 (M^+^), fragmented ion peak at 495, 293. The physical constant of all the compounds are given in [Table 1](#T0001){ref-type="table"}.

![Synthesis of 5-substituted pyrimidine analogs](IJPhS-71-672-g001){#F0001}

###### 

PHYSICAL CONSTANTS OF THE SYNTHESIZED COMPOUNDS

  Compd   R          R\'              R″                           Yield (%)   M.P(°)
  ------- ---------- ---------------- ---------------------------- ----------- ------------
  3a      4-CH~3~    \-               \-                           55          80-82
  3b      4-OCH~3~   \-               \-                           50          152-154
  3c      2-NO~2~    \-               \-                           55          60-62
  3d      4-NO~2~    \-               \-                           40          120-121
  3e      2-NH~2~    \-               \-                           50          160-161
  3f      \-         \-               \-                           45          Semi-solid
  3g      \-         \-               \-                           65          120-121
  4a      \-         2-OH             \-                           75          170-172
  4b      \-         4-OCH~3~         \-                           75          202-203
  4c      \-         3-OH, 4-OCH~3~   \-                           70          190-191
  4d      \-         4-Cl             \-                           75          210-213
  4e      \-         2-Cl             \-                           70          182-183
  4f      \-         \-               Thiophene-2-yl               65          206-208
  4g      \-         \-               2-Aminopyridin-3-yl          60          202-203
  4h      \-         \-               1,3- Diphenyl-pyrazol-4-yl   52          210-211

All the compounds showed poor activity against gram (−)ve bacteria *E. coli* ([Table 2](#T0002){ref-type="table"}). However compound 2 exhibited good antibacterial activity against gram (−)ve bacteria *P. aeruginosa* and good antifungal activity against both fungal strains *A. niger* and *A. terrus*. Compound 3d exhibited good antibacterial activity against gram (+)ve bacteria *S. aureus*. Compounds 3f exhibited good activity against *A. niger*. Compounds 4a, 4c and 4d showed good activity against *P. aeruginosa*. Compounds 4g and 4h exhibited good antibacterial activity against *P. aeruginosa, S. aureus* and *B. subtilis* and antifungal activity against both fungal strains. Other compounds have shown poor to moderate antibacterial and antifungal activity as compared to standard gentamycine and fluconazole. From the above results, it can be concluded that introduction of NO~2~, OH, Cl and heterocyclic moieties like pyridine and pyrazole to the pyrimidine analogs enhanced the antibacterial and antifungal activities.

###### 

ANTIMICROBIAL ACTIVITIES OF SYNTHESIZED COMPOUNDS

  Compd No        Dose (μg/ml)   Antibacterial Activity   Antifungal Activity                     
  --------------- -------------- ------------------------ --------------------- ----- ----- ----- -----
  2               1000           19                       05                    15    10    12    11
  3a              1000           07                       09                    10    11    17    17
  3b              1000           06                       08                    12    13    10    10
  3c              1000           07                       10                    10    11    12    11
  3d              1000           10                       05                    14    16    15    13
  3e              1000           08                       15                    11    14    13    12
  3f              1000           05                       10                    09    15    19    14
  3g              1000           19                       04                    10    11    10    10
  4a              1000           18                       07                    13    15    13    12
  4b              1000           15                       05                    12    12    11    15
  4c              1000           19                       04                    13    12    12    11
  4d              1000           18                       08                    10    10    10    12
  4e              1000           19                       06                    08    09    14    11
  4f              1000           10                       05                    15    12    15    10
  4g              1000           18                       07                    17    18    18    15
  4h              1000           16                       10                    20    18    16    15
  Control (DMF)   \-             Nil                      Nil                   Nil   Nil   Nil   Nil
  Gentamycine     1000           22                       19                    24    22    \-    \-
  Flucanazole     1000           \-                       \-                    \-    \-    22    20

Zone of inhibition excluding well size 6 mm

**Goudgaon *et al*.: Synthesis and antimicrobial activity of 5-iodopyrimidine analogs**
